Table 2: Patient characteristics.

Group A Group B -value

Age (year) 0.3925a
Sex (male/female)11/169/130.9905b
Smoking (yes/no)2/251/210.6740b
Alcohol intake (yes/no)12/1511/110.6983b
BMI (kg/m2) 0.3149a
Waist circumference (cm)
 Male 0.0435*a
 Female 0.9649a
SBP (mmHg) 0.7096a
DBP (mmHg) 0.5938a
TG (mg/dL) 0.6802a
HDL-cholesterol (mg/dL) 0.2515a
FPG (mg/dL) 0.9278a
Central obesity (yes/no)11/167/150.5193b
High blood pressure (yes/no)16/1113/90.9905b
Dyslipidemia (yes/no)12/1511/110.6983b
Hyperglycemia (yes/no)8/197/150.8687b
Concomitant drugs
 Calcium channel blocker (yes/no)8/197/150.8687b
 ARB or ACE inhibitor (yes/no)3/244/180.4817b
α or β blocker (yes/no)3/241/210.4038b
 Statin (yes/no)11/168/140.7544b
 Fibrate (yes/no)1/260/220.3618b
 Sulfonylurea (yes/no)3/241/210.4038b
 Thiazolidine analog (yes/no)3/240/220.1066b
α-glucosidase inhibitor (yes/no)2/251/210.6777b
 Antiplatelet drug (yes/no)1/260/220.3618b
Season test 1 performed6/14/5/29/5/8/00.0682b

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglyceride; HDL: high-density lipoprotein; FPG: fasting plasma glucose; central obesity, waist circumference ≥ 85 cm (male), ≥90 cm (female); high blood pressure,  mmHg and/or  mmHg; dyslipidemia,  mg/dL and/or HDL cholesterol < 40 mg/dL; hyperglycemia,  mg/dL; ARB: angiotensin II receptor blocker; ACE: angiotensin-converting enzyme; Spring: March 21 to June 20; Summer: June 21 to September 21; Fall: September 21 to December 20; Winter: December 21 to March 20.
aComparison between group A and group B by Wilcoxon test.
bComparison between group A and group B by Pearson’s chi-square test.
Data are expressed as mean ± S.E., .